The report will be delivered in 2-3 business days.

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

Starting Price : $5000 | Pages : 175 | Published : March 2021 | SKU CODE : 7730 | Format :


The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs.

The cancer monoclonal antibodies market covered in this report is segmented by monoclonal antibody therapies into bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux), panitumumab (vectibix), others and by application into breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others.

The global cancer monoclonal antibodies market is expected to grow from $45.51 billion in 2020 to $49.77 billion in 2021 at a compound annual growth rate (CAGR) of 9.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer monoclonal antibodies market is expected to reach $69.96 billion in 2025 at a CAGR of 9%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market.

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth.

Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer.

In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals.

The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global cancer monoclonal antibodies market is segmented -

1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others

2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others

3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Others

    1. Executive Summary

    2. Cancer Monoclonal Antibodies Market Characteristics

    3. Cancer Monoclonal Antibodies Market Trends And Strategies

    4. Impact Of COVID-19 On Cancer Monoclonal Antibodies

    5. Cancer Monoclonal Antibodies Market Size And Growth

    5.1. Global Cancer Monoclonal Antibodies Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Cancer Monoclonal Antibodies Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Cancer Monoclonal Antibodies Market Segmentation

    6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Bevacizumab (Avastin)

    Rituximab (Rituxan)

    Trastuzumab (Herceptin)

    Cetuximab (Erbitux)

    Panitumumab (Vectibix)

    Others

    6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Breast Cancer

    Blood Cancer

    Liver Cancer

    Brain Cancer

    Colorectal Cancer

    Others

    6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospitals and Clinics

    Research Laboratories

    Pharmacies

    Others

    7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Cancer Monoclonal Antibodies Market

    8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Cancer Monoclonal Antibodies Market

    9.1. China Cancer Monoclonal Antibodies Market Overview

    9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Cancer Monoclonal Antibodies Market

    10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Cancer Monoclonal Antibodies Market

    11.1. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Cancer Monoclonal Antibodies Market

    12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Cancer Monoclonal Antibodies Market

    13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Cancer Monoclonal Antibodies Market

    14.1. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Cancer Monoclonal Antibodies Market

    15.1. Western Europe Cancer Monoclonal Antibodies Market Overview

    15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Cancer Monoclonal Antibodies Market

    16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Cancer Monoclonal Antibodies Market

    17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Cancer Monoclonal Antibodies Market

    18.3. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Cancer Monoclonal Antibodies Market

    19.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

    19.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Cancer Monoclonal Antibodies Market

    20.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Cancer Monoclonal Antibodies Market

    21.1. North America Cancer Monoclonal Antibodies Market Overview

    21.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Cancer Monoclonal Antibodies Market

    22.1. USA Cancer Monoclonal Antibodies Market Overview

    22.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Cancer Monoclonal Antibodies Market

    23.1. South America Cancer Monoclonal Antibodies Market Overview

    23.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Cancer Monoclonal Antibodies Market

    24.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Cancer Monoclonal Antibodies Market

    25.1. Middle East Cancer Monoclonal Antibodies Market Overview

    25.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Cancer Monoclonal Antibodies Market

    26.1. Africa Cancer Monoclonal Antibodies Market Overview

    26.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    27.1. Cancer Monoclonal Antibodies Market Competitive Landscape

    27.2. Cancer Monoclonal Antibodies Market Company Profiles

    27.2.1. Amgen

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bristol Myers Squibb Company

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Eli Lilly and Company

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. F. Hoffmann-La Roche Ltd

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Genmab AS

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Cancer Monoclonal Antibodies Pipeline Analysis

    29. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

    30. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 27: Amgen Financial Performance
  • Table 28: Bristol Myers Squibb Company Financial Performance
  • Table 29: Eli Lilly and Company Financial Performance
  • Table 30: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 31: Genmab AS Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 27: Amgen Financial Performance
  • Figure 28: Bristol Myers Squibb Company Financial Performance
  • Figure 29: Eli Lilly and Company Financial Performance
  • Figure 30: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 31: Genmab AS Financial Performance
Global Cancer Monoclonal Antibodies Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Clinical Nutrition Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cervical Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Central Nervous System Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Checkpoint Inhibitors Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Culture Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell And Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Clinical Oncology Next Generation Sequencing Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Cancer biologics Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Cancer Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Blood And Blood Components Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Hematology Analyzers and Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Drugs For Hormonal Replacement Therapy Global Market Report 2021: COVID-19 Impact And Recovery To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)